Actively Recruiting
Study on Adjuvant Chemotherapy After Total Two-field Lymph Node Dissection of Thoracic Esophageal Squamous Cell Carcinoma
Led by Sun Yat-sen University · Updated on 2025-06-13
232
Participants Needed
1
Research Sites
489 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with thoracic esophageal squamous cell carcinoma after total two-field lymph node dissection were randomized into the adjuvant chemotherapy group or the postoperative observation group
CONDITIONS
Official Title
Study on Adjuvant Chemotherapy After Total Two-field Lymph Node Dissection of Thoracic Esophageal Squamous Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with esophageal squamous cell carcinoma who had radical surgery and total two-field lymph node dissection without prior neoadjuvant therapy and no serious postoperative complications
- Tumor stage T63 or lymph node stage N51, with more than 15 lymph nodes removed
- Age between 18 and 75 years
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- Adequate blood counts: neutrophils 1.5�D710^9/L, platelets 1.5�D710^9/L, hemoglobin 9 g/dL
- Adequate liver function: total bilirubin 1.5 times upper limit of normal, liver enzymes 2.5 times upper limit of normal
- Adequate kidney function: serum creatinine 1.5 times upper limit of normal, creatinine clearance 5 ml/min or higher
- Ability to understand and comply with study and follow-up procedures and provide informed consent
You will not qualify if you...
- History of other primary cancers or serious illnesses affecting study endpoints
- Serious postoperative complications affecting chemotherapy progress
- Contraindications to chemotherapy
- Women who are pregnant, breastfeeding, or planning pregnancy
- Inability to complete planned follow-up
- Lack of informed consent due to psychological, family, social, or other factors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen Uniersity Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
P
Peng Lin, professor
CONTACT
X
Xing Ru Ping
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here